Biotech Industry · eu
Novartis ends BioArctic brain-delivery collaboration; platform prospects and program decisions require separate assessment
BioArctic retains the $30 million upfront payment but loses the opportunity for subsequent milestones and royalties under the agreement. The company says Novartis’s decision to discontinue the program was unrelated to BrainTransporter technology, but the specific reasons and research data have not been disclosed.
Delivering antibodies into the brain is a challenge in developing drugs for brain diseases. Yet even when delivery technology fulfills its agreed role, a collaboration may still end alongside the drug program. Swedish biotech company BioArctic announced on November 2 that Novartis had decided to terminate their BrainTransporter collaboration, removing one route toward further development and commercialization for the brain-delivery platform.
The companies signed an option, collaboration and license agreement in August 2025 to combine BrainTransporter with an undisclosed Novartis antibody and explore potential new therapies. BioArctic’s announcement stated that the collaboration ended because Novartis discontinued the program, and that the decision was unrelated to BrainTransporter technology. Nordic Life Science also relayed this explanation in its November 3 report. However, the antibody’s identity, its target and the specific reasons for discontinuing development remain undisclosed.
BrainTransporter uses the transferrin receptor (TfR) to help drugs cross the blood-brain barrier. The platform is designed to improve the ability of drugs such as biologics to enter the brain, giving therapeutic molecules that are otherwise difficult to deliver a chance to reach their site of action. Whether this delivery capability translates into efficacy and safety for patients still requires validation through studies of each drug candidate; the termination announcement provided no relevant data.
Regarding the collaboration’s results, BioArctic CEO Gunilla Osswald said in an interview with EFN that the company had completed almost all deliverables ahead of schedule, describing the quality and results as good. She said Novartis had told the company that the decision was unrelated to BrainTransporter technology or the collaboration itself, but that she could not disclose the reasons behind it. These statements reflect BioArctic’s assessment of the collaboration; publicly available information remains insufficient to independently evaluate the research results.
The financial impact is clearer. BioArctic will retain the full $30 million upfront payment and recognize the remaining unrecognized portion as revenue in 2026; the announcement did not disclose the amount of that portion. This is an arrangement for recognizing revenue from an existing payment and does not represent a new payment from Novartis. Osswald also acknowledged that the subsequent milestone payments and sales royalties the company might have received had the original program progressed through to market launch have now been lost with the agreement’s termination.
The end of the collaboration has also reopened some scope for discussions. Osswald told EFN that the mechanism-of-action area covered by the original agreement is now available for other companies to pursue collaboration, although she still could not identify the mechanism. She also mentioned that BioArctic has four other ongoing collaborations. However, the ability to reopen discussions does not mean a replacement partner or a new deal is already in place.
The key distinction highlighted by this event is that the discontinuation of a single program cannot be directly equated with the platform’s performance. According to BioArctic’s current explanation, Novartis’s withdrawal was not due to a problem with the delivery technology; however, this also cannot be taken as proof of the platform’s efficacy. For BrainTransporter, whether subsequent collaborations can produce data open to public scrutiny is the next step in assessing its medical value.